Cprx stock price prediction

image

Stock Price Forecast

The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 9.00. The median estimate represents a +81.27% increase from the last price of 6.62.

Full
Answer

What is the price of cprx stock?

One share of CPRX stock can currently be purchased for approximately $4.97. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals has a market capitalization of $511.80 million and generates $119.07 million in revenue each year.

Is cprx a sell or buy on Robinhood?

Today CPRX ranks #14553 as sell candidate. Get a Free Stock at Robinhood Which way will CPRX go? Request * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

What is the upside from cprx Inc (cprx)?

Their average twelve-month price target is $7.88, predicting that the stock has a possible upside of 41.64%. The high price target for CPRX is $11.00 and the low price target for CPRX is $5.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

What is the average price target of a stock with a forecast?

The average price target is $7.75 with a high forecast of $9.00 and a low forecast of $6.50. The average price target represents a 40.65% change from the last price of $5.51. The highest, average, and lowest price target of all analysts.

See more

image


What does Catalyst Pharmaceuticals Inc do?

Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases.


Is CPRX undervalued?

Valuation. We believe that CPRX is currently undervalued at P/E GAAP of 8.13.


Is CPRX a good stock to buy?

Catalyst Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.


What kind of stock is CPRX?

Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy? Whether you’re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.


Will Cprx go up?

The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 9.00. The median estimate represents a +91.39% increase from the last price of 6.27.


What is Cprx Crypto?

CPRX is an Ethereum, ERC-20 based utility token. The Alliance itself may not sell any tokens during the first 12 months after the tokens are minted. CPRX may support other blockchains in the future and ultimately may move to its own custom blockchain if required.


Why did Cprx stock go up?

Virpax shares rise on expanded licensing deal for experimental drug. A Chester County pharmaceutical company’s stock was trading up more than 9% Tuesday morning after disclosing the expansion of its exclusive licensing agreement for an experimental antiviral drug candidate.


When did Catalyst Pharmaceuticals go public?

Announces Public Offering of Common Shares and Warrants. CORAL GABLES, Fla. , Oct. 28, 2011 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc.


What is Catalyst mean in stock market?

A catalyst in the markets can be anything that leads to a drastic change in a stock’s current price trend. The most common catalysts come in the form of new, often unexpected, information that causes the market to reevaluate a company’s business prospects.


Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Catalyst Pharmaceuticals in the last twelve months. Ther…


What is Catalyst Pharmaceuticals’ stock price forecast for 2022?

4 analysts have issued 1-year price targets for Catalyst Pharmaceuticals’ shares. Their forecasts range from $8.75 to $12.00. On average, they pred…


How has Catalyst Pharmaceuticals’ stock price performed in 2022?

Catalyst Pharmaceuticals’ stock was trading at $6.77 at the start of the year. Since then, CPRX shares have decreased by 1.3% and is now trading at…


When is Catalyst Pharmaceuticals’ next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast f…


How were Catalyst Pharmaceuticals’ earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.12 earn…


What guidance has Catalyst Pharmaceuticals issued on next quarter’s earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) gui…


Who are Catalyst Pharmaceuticals’ key executives?

Catalyst Pharmaceuticals’ management team includes the following people: Mr. Patrick J. McEnany , Co-Founder, Chairman, Pres & CEO (Age 75, Pay…


Who are some of Catalyst Pharmaceuticals’ key competitors?

Some companies that are related to Catalyst Pharmaceuticals include CureVac (CVAC) , Harmony Biosciences (HRMY) , Indivior (INVVY) , Zai Lab (Z…


What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NV…


What is Catalyst Pharmaceuticals’s consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Catalyst Pharmaceuticals stock is Buy based on the current…


Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors?

Analysts like Catalyst Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for Catalyst Pharmaceutical…


Do MarketBeat users like Catalyst Pharmaceuticals more than its competitors?

MarketBeat users like Catalyst Pharmaceuticals stock more than the stock of other Medical companies. 75.54% of MarketBeat users gave Catalyst Pharm…


Does Catalyst Pharmaceuticals’s stock price have much upside?

According to analysts, Catalyst Pharmaceuticals’s stock has a predicted upside of 52.89% based on their 12-month price targets.


What analysts cover Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has been rated by Piper Sandler , and Truist Financial in the past 90 days.


Signals & Forecast

The Catalyst Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.


Support, Risk & Stop-loss

On the downside, the stock finds support just below today’s level from accumulated volume at $6.99 and $6.92. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Catalyst Pharmaceuticals finds support just below today’s level at $6.99.


Is Catalyst Pharmaceuticals stock A Buy?

Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Catalyst Pharmaceuticals stock to perform well in the short-term period. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy candidate.


Insiders are positive buying more shares than they are selling in Catalyst Pharmaceuticals

In the last 100 trades there were 3.64 million shares bought and 1.56 million shares sold. The last trade was done 11 days ago by Miller Steve who bough 41 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.


About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases.


Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!


Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.


Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).


Analyst Ratings By Month

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.


Average Share Price and Price Target by Month

The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target.


Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Ratings Frequently Asked Questions

According to the issued ratings of 3 analysts in the last year, the consensus rating for Catalyst Pharmaceuticals stock is Buy based on the current 3 buy ratings for CPRX. The average twelve-month price target for Catalyst Pharmaceuticals is $9.50 with a high price target of $12.00 and a low price target of $7.00.


Stock Price Forecast

The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 8.00. The median estimate represents a +59.47% increase from the last price of 7.53.


Analyst Recommendations

The current consensus among 5 polled investment analysts is to Buy stock in Catalyst Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Buy rating. Move your mouse over past
months for detail


Analyst price target for CPRX

Based on 1 analyst offering 12 month price targets for Catalyst Pharmaceuticals Inc.


CPRX earnings per share forecast

What is CPRX ‘s earnings per share in the next 3 years based on estimates from 5 analyst s?


CPRX revenue forecast

What is CPRX ‘s revenue in the next 3 years based on estimates from 4 analyst s?


CPRX earnings growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?


CPRX revenue growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?


Crypto Perx price prediction based on worldwide money flows

Correlation of cryptocurrency capitalization and global money supply Predictions are no guarantees for the future. Use any projections and data on CoinDataFlow is for informational purposes. Information should not be considered investment advice.


Crypto Perx forecast and prediction overview

You may ask questions like: “Should I invest in Crypto Perx now?”, “Should I buy cprx today?”, “Will Crypto Perx be a good or bad investment in short-term, long-term period?”.

image

Leave a Comment